AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
VST Platform
Innovative science
Viral infections can be life-threatening for immunocompromised patients and in most cases, there are no effective treatment options.
There is an urgent need for therapies to treat and prevent these devastating viral infections and diseases in vulnerable patient populations with immune deficiencies, such as transplant recipients, cancer patients receiving chemotherapy, the elderly and the very young.
There is an urgent need for therapies to treat and prevent these devastating viral infections and diseases in vulnerable patient populations with immune deficiencies, such as transplant recipients, cancer patients receiving chemotherapy, the elderly and the very young.
Restoring Immunity
AlloVir’s investigational therapies aim to restore viral immunity in immunocompromised patients through the adoptive transfer of VSTs. Our cells have been prospectively generated from healthy, eligible donors, and as off-the-shelf therapies, they are immediately available for patients with T-cell deficiencies, who are at risk from the life-threatening consequences of viral diseases.
AlloVir’s Proprietary, Highly Efficient and Industrialized Platform Provides Key Advantages
The heroic role of T cells fighting viral infections
In healthy individuals, T cells from the body’s natural defense system provide protection against devastating viruses. For patients with T cell deficiencies, viruses may be uncontrolled, leading to potentially devastating and life-threatening consequences.
Virus-Specific T Cells Play a Central Role in Response to Viral Infection
Adaptive Cellular Immune Response in a Healthy Individual: Virus-specific T cell responses are vital components in cellular immunity against devastating viruses.